FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Arjona Ferreira Juan Camilo</u>						2. Issuer Name and Ticker or Trading Symbol  Myovant Sciences Ltd. [ MYOV ]									all applic	r 10		10% Ov	to Issuer % Owner her (specify	
	OVANT SO	irst) CIENCES INC. NT PARKWAY, 9	(Middle) 9TH FL	OOR		3. Date of Earliest Transaction (Month/Day/Year) 03/19/2021								X	Officer (give title below) Othe below Chief Medical Officer				эрсспу	
(Street) BRISBA	NE C.	A !	94005		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								i. Indiv ine) X	Form f	al or Joint/Group Filing (Check Applicable orm filed by One Reporting Person orm filed by More than One Reporting erson				
(City)	(S		(Zip)	D								f D-		- 11 1	0					
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)			ction	ion 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Disposed Of		es Acquired	i (A) or	5. Amoun		nt of 6. Of Formally (D) (Following (I) (II)		n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	tion(s)			(111501.4)	
Common Shares 03/19/20					2021				М		7,000	A	\$7.	78	141	1,535		D		
Common Shares 03/19/20				2021				S		7,000(1)	D	\$24.	17 <sup>(2)</sup>	7 <sup>(2)</sup> 134,535			D			
		Т	able II								osed of converti				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/E	n Date,	4. Transa Code ( 8)		on of		6. Date Exercis Expiration Date (Month/Day/Ye		te	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se (In	B. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amour or Number of Shares	er						
Stock Option (Right to Buy)	\$7.78	03/19/2021			М			7,000	(3)		04/15/2028	Common Shares	7,000	)	\$0.00	73,550	)	D		

## **Explanation of Responses:**

- 1. Shares sold pursuant to a 10b5-1 trading plan.
- 2. The shares were sold at prices ranging from \$24.01 to \$24.42. The reporting person will provde upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of
- 3. 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date

## Remarks:

/s/ Matthew Lang, Attorney-in-03/23/2021 **fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.